ALT

Altimmune, Inc. [ALT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALT Stock Summary

Top 10 Correlated ETFs

ALT

Top 10 Correlated Stocks

ALT

In the News

ALT Financial details

Company Rating
-
Market Cap
566.45M
Income
-86.76M
Revenue
426K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.34
Forward P/E
-
PEG
7.94
P/S
2257
P/B
4.18
P/C
-
P/FCF
-11.24
Quick Ratio
12.24
Current Ratio
12.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.62
EPS next Y
-
EPS next Q
-
EPS this Y
-8.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.25%
Revenue last 5Y
-40.68%
Revenue Q/Q
-89.78%
EPS Q/Q
38.46%
-
-
-
-
SMA20
-4.73%
SMA50
-28.41%
SMA100
-10.66%
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-45%
ROC
-0.55%
Gross Margin
61%
Oper. Margin
-30609%
Profit Margin
-27007%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.09-14.84
52W High
-54.07%
52W Low
+221.5%
RSI
42.82
Rel Volume
0.32
Avg Volume
5.18M
Volume
1.64M
Perf Week
2.23%
Perf Month
-12.04%
Perf Quarter
-0.77%
Perf Half Y
-6.4%
-
-
-
-
Beta
0.059
-
-
Volatility
0.19%, 0.29%
Prev Close
-3.02%
Price
6.43
Change
-5.44%

Something similar

Top by Market Cap
BRH.DE
GOOG
3V64.DE
EMBASSY.NS
MSFT
Top Correlated ETFs
FLQM
IJJ
MDYV
IVOV
WBIG
Top Correlated Stocks
APLS
PWP
BX
PFSI
STRO
Similar Market Cap
MOGB.L
1725.HK
XUEK.DE
OPTOCIRCUI.NS
PTMC

Company Profile

Healthcare Biotechnology
  • Volume Average 5.18M
  • Market Capitalization 566.45M
  • Employee 59
  • CEO Dr. Vipin K. Garg Ph.D.
  • Headquarters Gaithersburg,MD,US
  • IPO Date 2017-05-26
  • Website https://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.